Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 32 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
OLYS Pharma from La Hulpe, company number BE0754895372, closed financial year 2025 with a result of € 14,126 after tax. For that financial year OLYS Pharma recorded a gross margin of € 158,424 and equity of € 578,974. Compared with financial year 2024, the result moved from € 533,570 to € 14,126. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.
€ 578,974
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 14,126
▼ 97% vs 2024
Profit after tax over the fiscal year.
€ 19,124
▼ 89% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -91,406.
Debts at end 2025
€ 200,000
Loans from banks and other lenders, long and short.
€ 4,363
▼ 74% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -176,316 | € -79,500 | € 634,961 | € 158,424 | ▼ 75% |
| Profit after taxes | € -220,969 | € -189,895 | € 533,570 | € 14,126 | ▼ 97% |
| Equity | € -1,827 | € -191,722 | € 564,848 | € 578,974 | ▲ 3% |
| Total debts | € 295,711 | € 502,287 | € 467,901 | € 455,632 | ▼ 3% |
| Cash | € 13,844 | € 902 | € 166,591 | € 19,124 | ▼ 89% |
| Retained profit | € -449,208 | € -639,102 | € -105,533 | € -91,406 | ▲ € 14,126 |
| Bank debt | € 200,000 | € 200,000 | € 200,000 | € 200,000 | |
| Balance sheet total | € 293,883 | € 310,565 | € 1,032,748 | € 1,034,606 |
Key figures of OLYS Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OLYS Pharma?
What happened at OLYS Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 14,126 (▼ 97% vs 2024). Source: NBB ↗
- New establishment in Verlaine. KBO
- Start of the company according to the CBE. KBO
In short
From € 220,969 loss in 2022 to € 14,126 profit in 2025.
Best year ever: 2024, with € 533,570 profit.
Establishments
Establishment units
Physical locations of this company
Avenue Wolfers 32
1310 La Hulpe
Chemin de l'Yerne(VER) 6-B
4537 Verlaine
Active since 25 September 2020
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
OVH Mail
Hosting
OVH, FR
DNS
OVH DNS
Domain
Domain
olyspharma.com
Registered
2020-05-14
Registrar
OVH, SAS
Expires
2026-05-14
Website info
Features
Security
Network
Details
- Company number
- 0754.895.372
- VAT number
- BE 0754.895.372
- Registered office
- Avenue Wolfers 32, 1310 La Hulpe
- Names & denominations
- OLYS Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 September 2020
- Peppol
- Active · Active since 15 Dec 2025
- Contact
- olyspharma.com [email protected]
- Activities · NACE
Vervaardiging van geneesmiddelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied